Ifosfamide and etoposide salvage treatment in advanced ovarian cancer.
Twelve FIGO stage III-IV ovarian cancer patients progressing or relapsing after primary cisplatin-containing combination chemotherapy were treated with ifosfamide and etoposide. Only patients with clinically evaluable disease entered the trial. The 12 patients received a median number of 3 courses (range 1-6). No complete or partial response and two disease stabilizations were observed. Ten patients progressed on therapy. The combination of ifosfamide and etoposide does not appear to be an effective salvage treatment for advanced ovarian cancer.
Bruzzone
M
M
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Campora
E
E
Merlini
L
L
Giudici
S
S
Bottero
G
G
Iskra
L
L
Donadio
M
M
Ferrari
I
I
Ragni
N
N
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016879:Salvage Therapy
D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide